Welcome to Sanzyme, we are amongst the
first to offer contract manufacturing of
human-derived Gonadotropins, for the world.
It is possible because we’ve been making Gonadotropins for over a half century.
Welcome to Sanzyme, we are amongst the first to offer contract manufacturing of human-derived Gonadotropins, for the world. It is possible because we’ve been making Gonadotropins for over a half century.
Our experience in the 3 Cs - Certifications, CTDs and our Capacity puts us in a unique position as a collaborator and partner in success for many of the world’s leading pharmaceutical brands.
EU GMP CERTIFIED
DOSSIERS IN e-CTDs
CAPACITY OF 10+ MILLION VIALS / PER ANNUM
Globally, we help couples and prospective parents with our Infertility Drugs, and today our portfolio also includes Sex Hormones and Specialty Probiotics. We are widely regarded for our pioneering work in the IVF and Assisted Reproductive Technology space.
MILESTONES
OUR PRESENCE
Currently we operate in emerging markets with our distribution partners and in house brands.
We are open for Out Licensing / Co-development / other models of collaboration, as we expand our footprints to highly regulated markets.
We at Sanzyme are fully aware and prepared of dynamic regulatory landscape in the segment of Biologics/Biosimilars.
Armed with EU GMP & PIC/s for our Finished Formulations, we offer our e-CTD to cater to global regulatory requirements.
Navneet Battu (Vice President – International Business) (navneet.battu@sanzyme.com)
Navneet Battu (Vice President – International Business) (navneet.battu@sanzyme.com)
Navneet Battu (Vice President – International Business) (navneet.battu@sanzyme.com)
Yamini Prasad (yaminiprasad.kandru@sanzyme.com) and Navneet Battu (Vice President – International Business) (navneet.battu@sanzyme.com)
Pundeep Chaparala (pundeep.chaparala@sanzyme.com) and Navneet Battu (Vice President – International Business) (navneet.battu@sanzyme.com)
Navneet Battu (Vice President – International Business) (navneet.battu@sanzyme.com)
Corporate Communication and...
RECENT NEWS
Since 1969, when we entered into a Joint Venture with Sankyo (now Daiichi-Sankyo) to make gonadotropins to export to Japan, we’ve been at the forefront of biological hormones, and today we have the necessary technological foundation to do path breaking work.